Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
03 May 2018 Increased Germline and Tumour Mutation Testing Recommended in Adolescent and Young Adults with Cancer Cancer in Special Situations - Personalised medicine
02 May 2018 FDA Approves Dabrafenib Plus Trametinib for Adjuvant Treatment of Melanoma with BRAF V600E or V600K Mutations, as Detected by an FDA-Approved Test Melanoma and other skin tumours - Anticancer agents & Biologic therapy
30 Apr 2018 EMA Recommends Extension of Indications for Osimertinib Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
30 Apr 2018 EMA Recommends Extension of Indications for Pertuzumab Breast cancer - Personalised medicine - Anticancer agents & Biologic therapy
27 Apr 2018 Poziotinib as a Clinically Active Inhibitor of EGFR and HER2 exon 20 mutations Lung and other thoracic tumours - Translational research - Anticancer agents & Biologic therapy
26 Apr 2018 Genetic Subtypes of DLBCL Uncovered Haematologic malignancies - Translational research
25 Apr 2018 Large National Sequencing Projects in Europe Personalised medicine
24 Apr 2018 Information on Eligibility and Enrolment of Obese Participants in Cancer Randomised Clinical Trials Underreported Epidemiology/Etiology/Cancer Prevention
23 Apr 2018 FDA Approves Fostamatinib Tablets for ITP Haematologic malignancies - Anticancer agents & Biologic therapy
20 Apr 2018 FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
19 Apr 2018 CheckMate 227 Reveals Tumour Mutational Burden as an Important and Independent Biomarker in Advanced NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
18 Apr 2018 FDA Approves Nivolumab/Ipilimumab Combination for Intermediate or Poor-Risk Advanced RCC Genitourinary cancers - Cancer Immunology and Immunotherapy
17 Apr 2018 FDA Finalises Guidances to Accelerate the Development of Reliable, Beneficial NGS-Based Tests Personalised medicine
16 Apr 2018 EMA to Review Risk of Dosing Errors with Methotrexate Anticancer agents & Biologic therapy
13 Apr 2018 ELCC 2018 News: New Data Support First-Line Osimertinib in Patients with NSCLC and Sensitising EGFR Mutation Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy